1. SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION. (5th August 2022) Authors: Leighl, Natasha; Bestvina, Christine; Patel, Jyoti; Le, Xiuning; Veillon, Remi; Anderson, Ian; Demedts, Ingel; Garassino, Marina Chiara; Mazières, Julien; Morise, Masahiro; Smit, Egbert; Eggleton, S Peter; O'Brate, Aurora; Otto, Gordon; Bruns, Rolf; Schumacher, Karl Maria; Paik, Paul Journal: Neuro-oncology advances Issue: Volume 4(2022)Supplement 1 Page Start: i22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience. (March 2022) Authors: Cui, Wanyuan; Brown, Nick; Brown, Victoria; Bulusu, Ramesh; Denton, Arshi; Evans, Joanne; Forster, Martin; Papadatos-Pastos, Dionysis; Pellegrino, Loredana; Walsh, Nessa; Bruns, Rolf; Otto, Gordon; Paik, Paul Journal: Lung cancer Issue: Volume 165(2022)Supplement 1 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION. (9th August 2021) Authors: Bestvina, Christine M; Le, Xiuning; Veillon, Remi; Anderson, Ian; Patel, Jyoti; Demedts, Ingel; Garassino, Marina; Mazières, Julien; Morise, Masahiro; Smit, Egbert; Eggleton, S Peter; O'Brate, Aurora; Otto, Gordon; Bruns, Rolf; Schumacher, Karl Maria; Paik, Paul Journal: Neuro-oncology advances Issue: Volume 3(2021)Supplement 3 Page Start: iii5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗